Document Detail


Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions.
MedLine Citation:
PMID:  20546289     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: The reduced levels of glucagon-like peptide 1 (GLP-1) after an oral glucose load in Type 2 diabetic patients could be dependent either on a reduced synthesis or an increased degradation; but GLP-1 and dipeptidyl peptidase IV (DPP-IV) levels during an oral glucose tolerance test (OGTT) have not been studied together. The aim of the present study was to investigate GLP-1 and DPP-IV levels during an OGTT in patients with different degrees of glucose tolerance.
METHODS: Fifty six subjects (34 female, 22 male) matched for sex, age, body mass index (BMI) and waist circumference underwent a 75 g oral glucose tolerance test. Twenty-eight had normal glucose tolerance, 15 had impaired glucose tolerance and 13 had Type 2 diabetes mellitus. GLP-1 assay was performed with an ELISA kit, and DPP-IV assay using a colorimetric method.
RESULTS: At 30 min GLP-1 levels were significantly lower in subjects with impaired glucose tolerance and type 2 diabetes mellitus compared to those with normal glucose tolerance. The area under the GLP-1 curve was significantly different among the three groups; there was a significant decrease between subjects with normal and impaired glucose tolerance(P = 0.004) and between those with normal glucose tolerance and type 2 diabetes mellitus. (P < 0.001), while the area under the curve for DPP-IV showed no significant difference between the groups.
CONCLUSIONS: These results suggest that an increase of GLP-1 degradation does not play a role in the early stages of diabetes mellitus.
Authors:
L Pala; S Ciani; I Dicembrini; G Bardini; B Cresci; A Pezzatini; S Giannini; E Mannucci; C M Rotella
Related Documents :
16488579 - Glp-1 based therapy for type 2 diabetes.
19444259 - Incretin-based therapies for type 2 diabetes mellitus.
17352679 - 11 years of cyanopyrrolidines as dpp-iv inhibitors.
2693029 - A supplementary infusion of glucose-dependent insulinotropic polypeptide (gip) with a m...
12697069 - Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.
11527989 - Agonist-dependent failure of neutrophil function in diabetes correlates with extent of ...
19822169 - Critical determinants of hypothalamic appetitive neuropeptide development and expressio...
17307059 - Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
3698779 - Vitreous fluorophotometry in patients with no or minimal diabetic retinopathy.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetic medicine : a journal of the British Diabetic Association     Volume:  27     ISSN:  1464-5491     ISO Abbreviation:  Diabet. Med.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-15     Completed Date:  2011-01-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8500858     Medline TA:  Diabet Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  691-5     Citation Subset:  IM    
Affiliation:
Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence, Florence, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Area Under Curve
Body Mass Index
Diabetes Mellitus, Type 2 / metabolism*
Dipeptidyl Peptidase 4 / metabolism*
Fasting / metabolism
Female
Glucagon-Like Peptide 1 / metabolism*
Glucose Tolerance Test
Humans
Male
Middle Aged
Waist Circumference
Chemical
Reg. No./Substance:
89750-14-1/Glucagon-Like Peptide 1; EC 3.4.14.5/Dipeptidyl Peptidase 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Providing diabetes patients with personalized written clinical information in the diabetes outpatien...
Next Document:  Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabet...